Teligent, Inc.
TLGTQ
Other OTC0.00
USD
- -
- -
CIK
0000352998
Return %
Stock
S&P500
1Y
- -
19.25
3Y
100.00
65.11
5Y
-98.85
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 142
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 105 Lincoln Avenue Buena NJ United States of America 08310
- IPO Date
- Jul 30, 1981
- CIK
- 0000352998
- Website
- teligent.com
- Similar Companies
- Business
- Teligent, Inc. is a specialty generic pharmaceutical company that develops, manufactures, and sells topical, injectable, complex, and ophthalmic pharmaceutical products primarily in the United States and Canada. Its product portfolio includes hospital-based sterile injectable products such as cephalosporins (Cefotan, Fortaz, Zinacef), topical creams (Synalar, Spectazole), lotions (Kenalog), ointments (Topicort, Kenalog), and topical solutions (Pennsaid, Xylocaine). The company also provides contract development and manufacturing services to the prescription, over-the-counter pharmaceutical, and cosmetic markets. Teligent operates a 33,000 square-foot manufacturing and research complex in Buena, New Jersey, and maintains operations in Canada and Estonia. Recently, Teligent underwent significant structural changes, including the sale of its Canadian sterile injectable assets to Hikma Pharmaceuticals in early 2022, which expanded Hikma's presence in the Canadian injectables market. This asset sale included a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products, and a pipeline of additional products. Teligent previously filed for Chapter 11 bankruptcy in 2021 and subsequently reorganized its business operations. The company continues to focus on its core specialty generic pharmaceutical markets in the U.S., maintaining a product line of approximately 37 generic topical pharmaceuticals alongside branded injectable products under its own label. Founded in 1977 and headquartered in Buena, New Jersey, Teligent, Inc. targets healthcare providers, hospitals, and pharmacies in North America. It serves various markets including pharmaceutical prescription drugs for dermatological and hospital applications. The company's strategy revolves around specialty generic prescription drugs with a focus on topical, injectable, complex, and ophthalmic products, supported by contract manufacturing services for other pharmaceutical and cosmetic companies. Teligent employs approximately 200 people across its U.S. and international operations, maintaining a comprehensive portfolio of generic pharmaceutical offerings in its key geographic markets.